APC and carcinoma: CRCs that follow the polyp-adenoma-carcinoma pathway (accounting for the majority (70–80%) of CRC cases) typically possess 60% mutations in the adenomatous polyposis coli (APC) gene along with KRAS (45%) and TP53 (54%) mutations.